HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates electroCore (NASDAQ:ECOR) with a Buy and raises the price target from $2.75 to $7.
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer’s 20-Plus-Year Near Monopoly, Says Analyst
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
